Immunogenicity and Protection Efficacy of Monomeric and Trimeric Recombinant SARS Coronavirus Spike Protein Subunit Vaccine Candidates
Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease, and an effective vaccine is not available. In this study, we compared the immunogenicity and protection efficacy of recombinant proteins corresponding to different domains of the SARS-coronavirus spike protein. Trimeric...
Gespeichert in:
| Veröffentlicht in: | Viral immunology 2013-04, Vol.26 (2), p.126-132 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 132 |
|---|---|
| container_issue | 2 |
| container_start_page | 126 |
| container_title | Viral immunology |
| container_volume | 26 |
| creator | Li, Jie Ulitzky, Laura Silberstein, Erica Taylor, Deborah R. Viscidi, Raphael |
| description | Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease, and an effective vaccine is not available. In this study, we compared the immunogenicity and protection efficacy of recombinant proteins corresponding to different domains of the SARS-coronavirus spike protein. Trimeric recombinant proteins were created by fusing the foldon domain derived from T4 bacteriophage to the carboxy-termini of individual domains of the spike protein. While the full-length ectodomain (S) of the spike protein, the full-length ectodomain fused to foldon (S-foldon), the S1 domain (S1), S1-foldon, and the S2 domain(S2) antigens all elicited comparable antibody titers as measured by ELISA, S-foldon induced a significantly higher titer of neutralizing antibody and S2 protein did not elicit virus neutralizing antibodies. When tested in a mouse virus replication model, all the mice vaccinated with the S1, S1-foldon, S, or S-foldon were completely protected. |
| doi_str_mv | 10.1089/vim.2012.0076 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3624630</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2992515711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-3004931b7c1d96ea270a48751f4ae0f445f644cd1b5c5da006df91b9b11124c83</originalsourceid><addsrcrecordid>eNqFkU9rFDEYh4Modq0evUrAi5dZ83-Si1CWqoWK0q1eQyaTqakzyZpkFvYL-LnNOrWoF0_hzfvw8P74AfAcozVGUr3e-2lNECZrhFrxAKww520jVSseghWSkjSSMH4CnuR8ixCSQtLH4IRQ3lLVqhX4cTFNc4g3LnjrywGa0MNPKRZni48Bng-Dt8YeYBzghxji5JK3v6Dr5Jfhytk4dT6YUOD27GoLNzHFYPY-zRlud_6bW4Q-wO3czcEX-MVY64ODmyryvSkuPwWPBjNm9-zuPQWf355fb943lx_fXWzOLhvLuCoNRYgpirvW4l4JZ0iLDJMtxwMzDg2M8UEwZnvccct7g5DoB4U71WGMCbOSnoI3i3c3d5PrrQslmVHvahiTDjoar__eBP9V38S9poIwQVEVvLoTpPh9drnoyWfrxtEEF-esMSWiJQJLUdGX_6C3cU6hxquUEJRLhkilmoWyKeac3HB_DEb62LCuDetjw_rYcOVf_Jngnv5daQXoAhy_TQijd51L5T_an5rhtUE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1366358402</pqid></control><display><type>article</type><title>Immunogenicity and Protection Efficacy of Monomeric and Trimeric Recombinant SARS Coronavirus Spike Protein Subunit Vaccine Candidates</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Li, Jie ; Ulitzky, Laura ; Silberstein, Erica ; Taylor, Deborah R. ; Viscidi, Raphael</creator><creatorcontrib>Li, Jie ; Ulitzky, Laura ; Silberstein, Erica ; Taylor, Deborah R. ; Viscidi, Raphael</creatorcontrib><description>Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease, and an effective vaccine is not available. In this study, we compared the immunogenicity and protection efficacy of recombinant proteins corresponding to different domains of the SARS-coronavirus spike protein. Trimeric recombinant proteins were created by fusing the foldon domain derived from T4 bacteriophage to the carboxy-termini of individual domains of the spike protein. While the full-length ectodomain (S) of the spike protein, the full-length ectodomain fused to foldon (S-foldon), the S1 domain (S1), S1-foldon, and the S2 domain(S2) antigens all elicited comparable antibody titers as measured by ELISA, S-foldon induced a significantly higher titer of neutralizing antibody and S2 protein did not elicit virus neutralizing antibodies. When tested in a mouse virus replication model, all the mice vaccinated with the S1, S1-foldon, S, or S-foldon were completely protected.</description><identifier>ISSN: 0882-8245</identifier><identifier>EISSN: 1557-8976</identifier><identifier>DOI: 10.1089/vim.2012.0076</identifier><identifier>PMID: 23573979</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Animals ; Antibodies, Neutralizing - blood ; Antibodies, Viral - blood ; Antigens, Viral - genetics ; Antigens, Viral - immunology ; Disease Models, Animal ; Enzyme-Linked Immunosorbent Assay ; Membrane Glycoproteins - genetics ; Membrane Glycoproteins - immunology ; Mice ; Mice, Inbred BALB C ; Neutralization Tests ; Original ; Original Articles ; Protein Folding ; Protein Structure, Tertiary ; Recombinant Proteins - genetics ; Recombinant Proteins - immunology ; SARS Virus - genetics ; SARS Virus - immunology ; Severe Acute Respiratory Syndrome - prevention & control ; Spike Glycoprotein, Coronavirus ; Survival Analysis ; Vaccines, Subunit - administration & dosage ; Vaccines, Subunit - immunology ; Vaccines, Synthetic - administration & dosage ; Vaccines, Synthetic - immunology ; Viral Envelope Proteins - genetics ; Viral Envelope Proteins - immunology ; Viral Vaccines - administration & dosage ; Viral Vaccines - immunology</subject><ispartof>Viral immunology, 2013-04, Vol.26 (2), p.126-132</ispartof><rights>2013, Mary Ann Liebert, Inc.</rights><rights>(©) Copyright 2013, Mary Ann Liebert, Inc.</rights><rights>Copyright 2013, Mary Ann Liebert, Inc. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-3004931b7c1d96ea270a48751f4ae0f445f644cd1b5c5da006df91b9b11124c83</citedby><cites>FETCH-LOGICAL-c459t-3004931b7c1d96ea270a48751f4ae0f445f644cd1b5c5da006df91b9b11124c83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23573979$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Jie</creatorcontrib><creatorcontrib>Ulitzky, Laura</creatorcontrib><creatorcontrib>Silberstein, Erica</creatorcontrib><creatorcontrib>Taylor, Deborah R.</creatorcontrib><creatorcontrib>Viscidi, Raphael</creatorcontrib><title>Immunogenicity and Protection Efficacy of Monomeric and Trimeric Recombinant SARS Coronavirus Spike Protein Subunit Vaccine Candidates</title><title>Viral immunology</title><addtitle>Viral Immunol</addtitle><description>Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease, and an effective vaccine is not available. In this study, we compared the immunogenicity and protection efficacy of recombinant proteins corresponding to different domains of the SARS-coronavirus spike protein. Trimeric recombinant proteins were created by fusing the foldon domain derived from T4 bacteriophage to the carboxy-termini of individual domains of the spike protein. While the full-length ectodomain (S) of the spike protein, the full-length ectodomain fused to foldon (S-foldon), the S1 domain (S1), S1-foldon, and the S2 domain(S2) antigens all elicited comparable antibody titers as measured by ELISA, S-foldon induced a significantly higher titer of neutralizing antibody and S2 protein did not elicit virus neutralizing antibodies. When tested in a mouse virus replication model, all the mice vaccinated with the S1, S1-foldon, S, or S-foldon were completely protected.</description><subject>Animals</subject><subject>Antibodies, Neutralizing - blood</subject><subject>Antibodies, Viral - blood</subject><subject>Antigens, Viral - genetics</subject><subject>Antigens, Viral - immunology</subject><subject>Disease Models, Animal</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Membrane Glycoproteins - genetics</subject><subject>Membrane Glycoproteins - immunology</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Neutralization Tests</subject><subject>Original</subject><subject>Original Articles</subject><subject>Protein Folding</subject><subject>Protein Structure, Tertiary</subject><subject>Recombinant Proteins - genetics</subject><subject>Recombinant Proteins - immunology</subject><subject>SARS Virus - genetics</subject><subject>SARS Virus - immunology</subject><subject>Severe Acute Respiratory Syndrome - prevention & control</subject><subject>Spike Glycoprotein, Coronavirus</subject><subject>Survival Analysis</subject><subject>Vaccines, Subunit - administration & dosage</subject><subject>Vaccines, Subunit - immunology</subject><subject>Vaccines, Synthetic - administration & dosage</subject><subject>Vaccines, Synthetic - immunology</subject><subject>Viral Envelope Proteins - genetics</subject><subject>Viral Envelope Proteins - immunology</subject><subject>Viral Vaccines - administration & dosage</subject><subject>Viral Vaccines - immunology</subject><issn>0882-8245</issn><issn>1557-8976</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkU9rFDEYh4Modq0evUrAi5dZ83-Si1CWqoWK0q1eQyaTqakzyZpkFvYL-LnNOrWoF0_hzfvw8P74AfAcozVGUr3e-2lNECZrhFrxAKww520jVSseghWSkjSSMH4CnuR8ixCSQtLH4IRQ3lLVqhX4cTFNc4g3LnjrywGa0MNPKRZni48Bng-Dt8YeYBzghxji5JK3v6Dr5Jfhytk4dT6YUOD27GoLNzHFYPY-zRlud_6bW4Q-wO3czcEX-MVY64ODmyryvSkuPwWPBjNm9-zuPQWf355fb943lx_fXWzOLhvLuCoNRYgpirvW4l4JZ0iLDJMtxwMzDg2M8UEwZnvccct7g5DoB4U71WGMCbOSnoI3i3c3d5PrrQslmVHvahiTDjoar__eBP9V38S9poIwQVEVvLoTpPh9drnoyWfrxtEEF-esMSWiJQJLUdGX_6C3cU6hxquUEJRLhkilmoWyKeac3HB_DEb62LCuDetjw_rYcOVf_Jngnv5daQXoAhy_TQijd51L5T_an5rhtUE</recordid><startdate>20130401</startdate><enddate>20130401</enddate><creator>Li, Jie</creator><creator>Ulitzky, Laura</creator><creator>Silberstein, Erica</creator><creator>Taylor, Deborah R.</creator><creator>Viscidi, Raphael</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130401</creationdate><title>Immunogenicity and Protection Efficacy of Monomeric and Trimeric Recombinant SARS Coronavirus Spike Protein Subunit Vaccine Candidates</title><author>Li, Jie ; Ulitzky, Laura ; Silberstein, Erica ; Taylor, Deborah R. ; Viscidi, Raphael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-3004931b7c1d96ea270a48751f4ae0f445f644cd1b5c5da006df91b9b11124c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Antibodies, Neutralizing - blood</topic><topic>Antibodies, Viral - blood</topic><topic>Antigens, Viral - genetics</topic><topic>Antigens, Viral - immunology</topic><topic>Disease Models, Animal</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Membrane Glycoproteins - genetics</topic><topic>Membrane Glycoproteins - immunology</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Neutralization Tests</topic><topic>Original</topic><topic>Original Articles</topic><topic>Protein Folding</topic><topic>Protein Structure, Tertiary</topic><topic>Recombinant Proteins - genetics</topic><topic>Recombinant Proteins - immunology</topic><topic>SARS Virus - genetics</topic><topic>SARS Virus - immunology</topic><topic>Severe Acute Respiratory Syndrome - prevention & control</topic><topic>Spike Glycoprotein, Coronavirus</topic><topic>Survival Analysis</topic><topic>Vaccines, Subunit - administration & dosage</topic><topic>Vaccines, Subunit - immunology</topic><topic>Vaccines, Synthetic - administration & dosage</topic><topic>Vaccines, Synthetic - immunology</topic><topic>Viral Envelope Proteins - genetics</topic><topic>Viral Envelope Proteins - immunology</topic><topic>Viral Vaccines - administration & dosage</topic><topic>Viral Vaccines - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Jie</creatorcontrib><creatorcontrib>Ulitzky, Laura</creatorcontrib><creatorcontrib>Silberstein, Erica</creatorcontrib><creatorcontrib>Taylor, Deborah R.</creatorcontrib><creatorcontrib>Viscidi, Raphael</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Viral immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Jie</au><au>Ulitzky, Laura</au><au>Silberstein, Erica</au><au>Taylor, Deborah R.</au><au>Viscidi, Raphael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity and Protection Efficacy of Monomeric and Trimeric Recombinant SARS Coronavirus Spike Protein Subunit Vaccine Candidates</atitle><jtitle>Viral immunology</jtitle><addtitle>Viral Immunol</addtitle><date>2013-04-01</date><risdate>2013</risdate><volume>26</volume><issue>2</issue><spage>126</spage><epage>132</epage><pages>126-132</pages><issn>0882-8245</issn><eissn>1557-8976</eissn><abstract>Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease, and an effective vaccine is not available. In this study, we compared the immunogenicity and protection efficacy of recombinant proteins corresponding to different domains of the SARS-coronavirus spike protein. Trimeric recombinant proteins were created by fusing the foldon domain derived from T4 bacteriophage to the carboxy-termini of individual domains of the spike protein. While the full-length ectodomain (S) of the spike protein, the full-length ectodomain fused to foldon (S-foldon), the S1 domain (S1), S1-foldon, and the S2 domain(S2) antigens all elicited comparable antibody titers as measured by ELISA, S-foldon induced a significantly higher titer of neutralizing antibody and S2 protein did not elicit virus neutralizing antibodies. When tested in a mouse virus replication model, all the mice vaccinated with the S1, S1-foldon, S, or S-foldon were completely protected.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>23573979</pmid><doi>10.1089/vim.2012.0076</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0882-8245 |
| ispartof | Viral immunology, 2013-04, Vol.26 (2), p.126-132 |
| issn | 0882-8245 1557-8976 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3624630 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Animals Antibodies, Neutralizing - blood Antibodies, Viral - blood Antigens, Viral - genetics Antigens, Viral - immunology Disease Models, Animal Enzyme-Linked Immunosorbent Assay Membrane Glycoproteins - genetics Membrane Glycoproteins - immunology Mice Mice, Inbred BALB C Neutralization Tests Original Original Articles Protein Folding Protein Structure, Tertiary Recombinant Proteins - genetics Recombinant Proteins - immunology SARS Virus - genetics SARS Virus - immunology Severe Acute Respiratory Syndrome - prevention & control Spike Glycoprotein, Coronavirus Survival Analysis Vaccines, Subunit - administration & dosage Vaccines, Subunit - immunology Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - immunology Viral Envelope Proteins - genetics Viral Envelope Proteins - immunology Viral Vaccines - administration & dosage Viral Vaccines - immunology |
| title | Immunogenicity and Protection Efficacy of Monomeric and Trimeric Recombinant SARS Coronavirus Spike Protein Subunit Vaccine Candidates |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T20%3A27%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20and%20Protection%20Efficacy%20of%20Monomeric%20and%20Trimeric%20Recombinant%20SARS%20Coronavirus%20Spike%20Protein%20Subunit%20Vaccine%20Candidates&rft.jtitle=Viral%20immunology&rft.au=Li,%20Jie&rft.date=2013-04-01&rft.volume=26&rft.issue=2&rft.spage=126&rft.epage=132&rft.pages=126-132&rft.issn=0882-8245&rft.eissn=1557-8976&rft_id=info:doi/10.1089/vim.2012.0076&rft_dat=%3Cproquest_pubme%3E2992515711%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1366358402&rft_id=info:pmid/23573979&rfr_iscdi=true |